Small Molecules
26 February 2020
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer26 February 2020
SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)26 February 2020
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF After Planned Interim Analysis26 February 2020
iOnctura Announces First Patient Dosed in a Phase I Clinical Study of its Novel Highly Selective PI3Kδ Inhibitor, IOA-244 for Solid Tumours26 February 2020
NIH clinical trial of remdesivir to treat COVID-19 begins26 February 2020
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis25 February 2020
FDA Grants IND Approval to Promising Anti-Cancer Agent Veyonda®24 February 2020
Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes24 February 2020
United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints22 February 2020
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine21 February 2020
AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis20 February 2020
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting20 February 2020
DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors20 February 2020
Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout20 February 2020
Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint19 February 2020
Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis18 February 2020
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL50118 February 2020
FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE AttacksNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports